The Cardioprotective Effect of Intralipid in Decreasing the Ischemic Insults During Off-pump Coronary Artery Revascularization

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04806425

Enrollment

Registered

2021-03-19

Start date

2020-10-01

Completion date

2021-03-01

Last updated

2021-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Brief summary

the aim of the study is to assess the effect of intralipid as regard efficiency in decreasing myocardial ischemia , given during preconditioning in off pump coronary artery revascularization

Interventions

DRUGIntralipid

intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia

DRUGPlacebo

normal saline is given in same volume to normal saline group over the same duration

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 75 Years

Healthy volunteers

Inclusion criteria

* patients between 40 to 75 undergoing off bump CABG surgery

Exclusion criteria

* emergency surgery * Ejection fraction less than 50% * redo procedures * history of allergy to peanuts

Design outcomes

Primary

Measure	Time frame	Description
ICU stay	long icu stay is considered if more than 7 days	measuring the duration of stay in the ICU

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026